Analyst Viewpoint
Technological advancements, increase in awareness, and evolving treatment modalities are driving the global market. Cognitive disorders encompass a spectrum of conditions affecting cognitive function, including but not limited to Alzheimer's disease, dementia, and attention-deficit/hyperactivity disorder (ADHD). Rise in the global geriatric population is another key factor driving market expansion. Furthermore, surge in investment in research and development is expected to bolster the global cognitive disorders treatment market size during the forecast period.
Advancements in therapeutic approaches offers lucrative opportunities to market players. Pharmaceutical companies are focusing on research & development to introduce novel cognitive disorder therapies in order to increase cognitive disorders treatment market share.
Cognitive disorders represent a spectrum of conditions characterized by impairment in cognitive functions, including memory, attention, language, and problem-solving. These disorders, such as Alzheimer's disease, Parkinson's disease, and vascular dementia, pose significant challenges to affected individuals and their caregivers.
The field of cognitive disorders treatment has witnessed a paradigm shift in the past few years, with a growing emphasis on multidisciplinary approaches and targeted interventions.
Pharmacological interventions are a cornerstone in the management of cognitive disorders. Advances in neuropharmacology have led to the development of medications targeting specific neurotransmitter systems implicated in cognitive function.
Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, have demonstrated efficacy in enhancing cognitive performance and mitigating symptom progression in Alzheimer's disease. Additionally, memantine, an NMDA receptor antagonist, has shown promise in managing moderate to severe cognitive impairment.
Ongoing research seeks to unravel the intricate neurobiological mechanisms underlying these disorders, paving the way for the development of novel therapeutic modalities. As the understanding of cognitive disorders deepens, integration of diverse treatment modalities offers hope for improving outcomes and enhancing the quality of life for individuals grappling with these challenging conditions.
Rise in prevalence of cognitive disorders has become a significant public health concern, with the geriatric population emerging as a pivotal driver of the global cognitive disorders treatment market demand.
As populations across the globe experience a demographic shift toward older age groups, the incidence of cognitive disorders, such as Alzheimer's disease and dementia, has witnessed a corresponding surge.
According to data from the World Health Organization (WHO), the global population aged 60 and above is projected to nearly double by 2050, reaching approximately 22% of the world's population. This demographic shift is particularly pronounced in developed nations, where aging is more rapid.
In the U.S., the Administration on Aging reports a substantial increase in the elderly population, with individuals aged 65 and older expected to comprise 21.7% of the population by 2040, up from 15.2% in 2016. This demographic segment is highly susceptible to cognitive disorders, with Alzheimer's disease affecting an estimated 5.8 million people in 2020.
In Europe, this pattern is mirrored, with Eurostat projecting that the percentage of people aged 65 and older is anticipated to reach 29.1% by 2050. Within this demographic cohort, the prevalence of dementia is anticipated to rise sharply, necessitating an intensified focus on cognitive disorder treatment and management.
These demographic shifts underline the imperative for sustained research and development in the cognitive disorders treatment market. As the aging population burgeons, innovative therapeutic interventions and pharmaceutical solutions, such as memory loss management and cognitive function enhancement, become paramount to address the escalating burden of cognitive disorders.
The landscape of cognitive disorders treatment has undergone a transformative shift, with advancements in diagnosis and treatment emerging as a pivotal driver of the market. Focus on precision medicine and technological innovations has ushered in a new era, fostering tailored therapeutic approaches for cognitive disorders, such as cognitive impairment therapy. This paradigm shift is not only reshaping patient outcomes, but also propelling the cognitive disorders treatment market demand.
In the past few years, breakthroughs in neuroimaging technologies have significantly enhanced diagnostic accuracy, allowing for early detection of cognitive disorders.
According to a report by the World Health Organization (WHO), advancements in brain imaging, such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI), have played a crucial role in unraveling the intricacies of cognitive disorders at a molecular and cellular level. This has enabled clinicians to make more informed treatment decisions, leading to improved patient outcomes.
The advent of biomarker discovery and analysis has further revolutionized the diagnostic landscape. Identification of specific biomarkers associated with cognitive disorders allows for early detection, enabling interventions at the pre-symptomatic stage.
Treatment modalities have also evolved in tandem with diagnostic advancements. Pharmaceutical interventions, including disease-modifying therapies, have witnessed a surge in development.
The shift toward advancements in diagnosis and treatment is driving global cognitive disorders treatment market growth. Integration of cutting-edge diagnostic technologies and development of targeted therapeutics underscore a promising trajectory for improving patient outcomes and advancing the overall landscape of cognitive disorders treatment.
The field of cognitive disorders treatment is witnessing profound transformation, attributed to increase in investment in research & development (R&D). The pivotal role of R&D in advancing therapeutic interventions for cognitive disorders has become a linchpin for market expansion and innovation.
Investment in R&D acts as a catalyst, propelling the global cognitive disorders treatment market by fostering a conducive environment for scientific exploration. These financial commitments are instrumental in supporting comprehensive research initiatives, ranging from the identification of novel biomarkers to the development of precision-targeted therapies.
The multifaceted nature of cognitive disorders necessitates a nuanced approach, and R&D investments empower researchers to explore diverse modalities, including pharmacological interventions, neuromodulation techniques, and cognitive rehabilitation strategies.
The growing investment landscape in R&D facilitates collaboration between academia, industry, and research institutions, fostering a robust ecosystem that accelerates the translation of scientific discoveries into tangible clinical applications.
This collaborative synergy not only expedites the drug development process, but also promotes the exploration of innovative diagnostic tools and personalized treatment approaches. The ripple effects of increased R&D investments are evident in the rapid expansion of the knowledge base surrounding cognitive disorders, enabling healthcare professionals to adopt more targeted and efficacious interventions.
North America accounted for the largest global cognitive disorders treatment market share in 2022. This is ascribed to robust research & development initiatives, led by leading pharmaceutical companies and academic institutions. The region's advanced healthcare infrastructure seamlessly integrates cutting-edge technologies, fostering efficient diagnosis and treatment.
Collaborations between industry giants and research entities facilitate knowledge exchange, driving accelerated advancements. High healthcare expenditure and increase in geriatric population are ascribed to North America’s market dominance.
According to cognitive disorders treatment market forecast, the industry in Asia Pacific is expected to grow at a rapid pace during the forecast period. This is ascribed to rise in prevalence of cognitive disorders among the geriatric population and increase in awareness and de-stigmatization of mental health issues.
Leading companies in the global cognitive disorders treatment market have adopted strategies such as merger & acquisition, collaborations, and new product launches in order to expand presence.
Eisai Co., Ltd., Novartis AG (Knight Therapeutics), Biogen, Inc., Takeda Pharmaceutical Company Limited, Dr. Reddy’s Laboratories Ltd., Adamas Pharmaceuticals, Inc., Allergan plc, Actavis plc, and H. Lundbeck A/S are the prominent players in the global cognitive disorders treatment market.
The cognitive disorders treatment market report profiles top players based on various factors such as company overview, financial summary, strategies, product portfolio, segments, and recent advancements.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 5.5 Bn |
| Forecast (Value) in 2031 | More than US$ 8.6 Bn |
| Growth Rate (CAGR) | 5.2% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional-level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 5.5 Bn in 2022
It is projected to reach more than US$ 8.6 Bn by 2031
The CAGR is anticipated to be 5.2% from 2023 to 2031
The Alzheimer's disease indication segment accounted for the largest share in 2022
North America is expected to a lucrative region during the forecast period.
Eisai Co., Ltd., Novartis AG (Knight Therapeutics), Biogen, Inc., Takeda Pharmaceutical Company Limited, Dr. Reddy’s Laboratories Ltd., Adamas Pharmaceuticals, Inc., Allergan plc, Actavis plc, and H. Lundbeck A/S.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cognitive Disorders Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cognitive Disorders Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Pipeline Analysis
5.3. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.4. COVID-19 Pandemic Impact on Industry
6. Global Cognitive Disorders Treatment Market Analysis and Forecast, By Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Indication, 2017–2031
6.3.1. Lewy Body Dementia
6.3.2. Parkinson's Disease Dementia
6.3.3. Alzheimer's Disease
6.3.4. Vascular Dementia
6.3.5. Other indications
6.4. Market Attractiveness Analysis, By Indication
7. Global Cognitive Disorders Treatment Market Analysis and Forecast, By Drug Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Type, 2017–2031
7.3.1. Cholinesterase Inhibitors
7.3.2. NMDA Antagonists & Combination Drugs
7.4. Market Attractiveness Analysis, By Drug Type
8. Global Cognitive Disorders Treatment Market Analysis and Forecast, By Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, By Distribution Channel
9. Global Cognitive Disorders Treatment Market Analysis and Forecast, By Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, By Region
10. North America Cognitive Disorders Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Indication, 2017–2031
10.2.1. Lewy Body Dementia
10.2.2. Parkinson's Disease Dementia
10.2.3. Alzheimer's Disease
10.2.4. Vascular Dementia
10.2.5. Other Indications
10.3. Market Value Forecast, by Drug Type, 2017–2031
10.3.1. Cholinesterase Inhibitors
10.3.2. NMDA Antagonists & Combination Drugs
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Indication
10.6.2. By Drug Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Cognitive Disorders Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Indication, 2017–2031
11.2.1. Lewy Body Dementia
11.2.2. Parkinson's Disease Dementia
11.2.3. Alzheimer's Disease
11.2.4. Vascular Dementia
11.2.5. Other Indications
11.3. Market Value Forecast, by Drug Type, 2017–2031
11.3.1. Cholinesterase Inhibitors
11.3.2. NMDA Antagonists & Combination Drugs
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Indication
11.6.2. By Drug Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Cognitive Disorders Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Indication, 2017–2031
12.2.1. Lewy Body Dementia
12.2.2. Parkinson's Disease Dementia
12.2.3. Alzheimer's Disease
12.2.4. Vascular Dementia
12.2.5. Other Indications
12.3. Market Value Forecast, by Drug Type, 2017–2031
12.3.1. Cholinesterase Inhibitors
12.3.2. NMDA Antagonists & Combination Drugs
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Indication
12.6.2. By Drug Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Cognitive Disorders Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Indication, 2017–2031
13.2.1. Lewy Body Dementia
13.2.2. Parkinson's Disease Dementia
13.2.3. Alzheimer's Disease
13.2.4. Vascular Dementia
13.2.5. Other Indications
13.3. Market Value Forecast, by Drug Type, 2017–2031
13.3.1. Cholinesterase Inhibitors
13.3.2. NMDA Antagonists & Combination Drugs
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Indication
13.6.2. By Drug Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Cognitive Disorders Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Indication, 2017–2031
14.2.1. Lewy Body Dementia
14.2.2. Parkinson's Disease Dementia
14.2.3. Alzheimer's Disease
14.2.4. Vascular Dementia
14.2.5. Other Indications
14.3. Market Value Forecast, by Drug Type, 2017–2031
14.3.1. Cholinesterase Inhibitors
14.3.2. NMDA Antagonists & Combination Drugs
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Indication
14.6.2. By Drug Type
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Eisai Co., Ltd.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Novartis AG (Knight Therapeutics)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Biogen, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Takeda Pharmaceutical Company Limited
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Dr. Reddy’s Laboratories Ltd.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Adamas Pharmaceuticals, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Allergan plc
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Actavis plc
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. H. Lundbeck A/S
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 02: Global Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 03: Global Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 06: North America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Indication, 2017–2031
Table 07: North America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2031
Table 08: North America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: Europe Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 10: Europe Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Indication, 2017–2031
Table 11: Europe Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2031
Table 12: Europe Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Asia Pacific Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 14: Asia Pacific Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 15: Asia Pacific Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Latin America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 18: Latin America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Indication, 2017–2031
Table 19: Latin America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2031
Table 20: Latin America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Middle East & Africa Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 22: Middle East & Africa Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 23: Middle East & Africa Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 24: Middle East & Africa Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 02: Global Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 03: Global Cognitive Disorders Treatment Market Value Share Analysis, By Indication, 2022 and 2031
Figure 04: Global Cognitive Disorders Treatment Market Attractiveness Analysis, By Indication, 2023–2031
Figure 05: Global Cognitive Disorders Treatment Market Value Share Analysis, By Distribution Channel, 2022 and 2031
Figure 06: Global Cognitive Disorders Treatment Market Attractiveness Analysis, By Distribution Channel, 2023–2031
Figure 07: Global Cognitive Disorders Treatment Market Value Share Analysis, by Region, 2022 and 2031
Figure 08: Global Cognitive Disorders Treatment Market Attractiveness Analysis, by Region, 2023–2031
Figure 09: North America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: North America Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 11: North America Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 12: North America Cognitive Disorders Treatment Market Value Share Analysis, By Indication, 2022 and 2031
Figure 13: North America Cognitive Disorders Treatment Market Attractiveness Analysis, By Indication, 2023–2031
Figure 14: North America Cognitive Disorders Treatment Market Value Share Analysis, By Distribution Channel, 2022 and 2031
Figure 15: North America Cognitive Disorders Treatment Market Attractiveness Analysis, By Distribution Channel, 2023–2031
Figure 16: North America Cognitive Disorders Treatment Market Value Share Analysis, by Country, 2022 and 2031
Figure 17: North America Cognitive Disorders Treatment Market Attractiveness Analysis, by Country, 2023–2031
Figure 18: Europe Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 19: Europe Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 20: Europe Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 21: Europe Cognitive Disorders Treatment Market Value Share Analysis, By Indication, 2022 and 2031
Figure 22: Europe Cognitive Disorders Treatment Market Attractiveness Analysis, By Indication, 2023–2031
Figure 23: Europe Cognitive Disorders Treatment Market Value Share Analysis, By Distribution Channel, 2022 and 2031
Figure 24: Europe Cognitive Disorders Treatment Market Attractiveness Analysis, By Distribution Channel, 2023–2031
Figure 25: Europe Cognitive Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 26: Europe Cognitive Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 27: Asia Pacific Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 28: Asia Pacific Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 29: Asia Pacific Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 30: Asia Pacific Cognitive Disorders Treatment Market Value Share Analysis, by Indication, 2022 and 2031
Figure 31: Asia Pacific Cognitive Disorders Treatment Market Attractiveness Analysis, by Indication, 2023–2031
Figure 32: Asia Pacific Cognitive Disorders Treatment Market Value Share Analysis, By Distribution Channel, 2022 and 2031
Figure 33: Asia Pacific Cognitive Disorders Treatment Market Attractiveness Analysis, By Distribution Channel, 2023–2031
Figure 34: Asia Pacific Cognitive Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 35: Asia Pacific Cognitive Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 36: Latin America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Latin America Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 38: Latin America Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 39: Latin America Cognitive Disorders Treatment Market Value Share Analysis, By Indication, 2022 and 2031
Figure 40: Latin America Cognitive Disorders Treatment Market Attractiveness Analysis, By Indication, 2023–2031
Figure 41: Latin America Cognitive Disorders Treatment Market Value Share Analysis, By Distribution Channel, 2022 and 2031
Figure 42: Latin America Cognitive Disorders Treatment Market Attractiveness Analysis, By Distribution Channel, 2023–2031
Figure 43: Latin America Cognitive Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 44: Latin America Cognitive Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 45: Middle East & Africa Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Middle East & Africa Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 47: Middle East & Africa Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 48: Middle East & Africa Cognitive Disorders Treatment Market Value Share Analysis, by Indication, 2022 and 2031
Figure 49: Middle East & Africa Cognitive Disorders Treatment Market Attractiveness Analysis, by Indication, 2023–2031
Figure 50: Middle East & Africa Cognitive Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: Middle East & Africa Cognitive Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 52: Middle East & Africa Cognitive Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 53: Middle East & Africa Cognitive Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 54: Global Cognitive Disorders Treatment Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cognitive Disorders Treatment Market
*86 figures and 60 tables includes